Haleon Boosts Sales by Targeting Side-Effects of Weight-Loss Drugs
Consumer health company Haleon has reported increased sales driven by products addressing side-effects from GLP-1 weight-loss drugs like Wegovy and Zepbound. These medications, which mimic a hormone to reduce appetite, can cause nausea, constipation, vomiting, and abdominal pain—conditions for which Haleon offers remedies such as Advil, TUMS, and Biotène. Haleon has partnered with U.S.-based retailers like CVS Pharmacy to place its products in both regular aisles and dedicated GLP-1 sections. This dual placement strategy led to an average 24% sales lift per store during the first quarter of this year. The company holds a majority share of GLP-1 shelf space at CVS, with curated items on these shelves outperforming those without. Approximately 11% of Americans are using GLP-1 drugs according to Gallup analytics. Haleon is also in discussions with Walmart and Target regarding similar strategies but has not disclosed the outcomes.
Tickers: $CVS $HLN $LLY $NVO $TGT $WMT
Topics: consumer health products GLP-1 drugs retail strategy sales growth